OPC-64005
 | This article, OPC-64005, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
| This article, OPC-64005, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
| Clinical data | |
|---|---|
| Other names | OPC64005 |
| Routes of administration | Oral[1] |
| Drug class | Serotonin–norepinephrine–dopamine reuptake inhibitor (triple reuptake inhibitor)[1] |
OPC-64005 is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), or "triple reuptake inhibitor" (TRI), which is under development for the treatment of major depressive disorder.[1][2][3] It was also under development for the treatment of attention deficit hyperactivity disorder (ADHD), but development for this indication was discontinued.[1][4] It is taken by mouth.[1]
As of December 2022, OPC-64005 is in phase 2 clinical trials for major depressive disorder.[1][2] It reached phase 2 clinical trials for ADHD prior to the discontinuation of its development for this use.[1] It completed a phase 2 clinical trial for ADHD comparing it with placebo and atomoxetine, but the results of this trial were not disclosed.[5] The drug is under development by Otsuka Pharmaceutical.[1][2] It is a small molecule, but its chemical structure does not appear to have been disclosed.[1][2]
References
- ^ a b c d e f g h i "OPC 64005". AdisInsight. 7 December 2022. Retrieved 22 October 2024.
- ^ a b c d "Delving into the Latest Updates on OPC-64005 with Synapse". Synapse. 17 October 2024. Retrieved 22 October 2024.
- ^ Rodríguez-Lavado J, Alarcón-Espósito J, Mallea M, Lorente A (August 2022). "A New Paradigm Shift in Antidepressant Therapy: From Dual-action to Multitarget-directed Ligands". Curr Med Chem. 29 (29): 4896–4922. doi:10.2174/0929867329666220317121551. PMID 35301942.
- ^ Nageye F, Cortese S (July 2019). "Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD". Expert Rev Neurother. 19 (7): 707–717. doi:10.1080/14737175.2019.1628640. PMID 31167583.
- ^ Williams OC, Prasad S, McCrary A, Jordan E, Sachdeva V, Deva S, Kumar H, Mehta J, Neupane P, Gupta A (May 2023). "Adult attention deficit hyperactivity disorder: a comprehensive review". Ann Med Surg (Lond). 85 (5): 1802–1810. doi:10.1097/MS9.0000000000000631. PMC 10205222. PMID 37228994.
 | This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |